Related Experiment Videos
Botulinum toxin type B: a new therapy for axillary hyperhidrosis
1Vascular Unit, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK. drlisanelson@hotmail.com
British Journal of Plastic Surgery
|February 16, 2005
Summary
Neurobloc (Botulinum toxin type B) effectively treats axillary hyperhidrosis, significantly reducing sweat production and improving patient satisfaction with minimal side effects. This offers a promising alternative for managing excessive underarm sweating.
Area of Science:
- Dermatology
- Neurology
- Medical Aesthetics
Background:
- Primary axillary hyperhidrosis significantly impacts quality of life, particularly in adolescents.
- Current treatments like Botulinum toxin type A (Botox) may lose efficacy due to antibody formation.
- Botulinum toxin type B (Neurobloc) presents a potentially less immunogenic alternative.
Purpose of the Study:
- To evaluate the effectiveness of Neurobloc for treating axillary hyperhidrosis.
- To assess patient outcomes and satisfaction with Neurobloc treatment.
Main Methods:
- A study involving thirteen patients with axillary hyperhidrosis.
- Quantification of hyperhidrotic areas using iodine-starch tests, measurements, and photographs.
- Subdermal administration of 5000 MU of Neurobloc, with assessments at 4, 8, and 12 weeks.
Main Results:
- Significant reduction in hyperhidrotic area by 81-87% at 12 weeks (p=0.001).
- 100% patient satisfaction reported throughout the study.
- Substantial decrease in subjective sweat production (90-98%) with minimal side effects.
Conclusions:
- Neurobloc demonstrates significant efficacy in treating axillary hyperhidrosis.
- The treatment leads to high patient satisfaction and considerable reduction in sweating.
- Neurobloc is a viable and effective therapeutic option for axillary hyperhidrosis.